RECORDATI ORD overview

Helsinn to co-host alongside Recordati Rare Diseases satellite symposium on MF-CTCL diagnosis optimization at European Academy of Dermatology and Venereology Congress 2019 Lugano, Switzerland , Puteaux, France, October 9, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces it will be co-hosting alongside Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, part of Recordati Group, a satellite symposium at the...

Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological Research Annual Meeting 2019 Lugano-Switzerland , Puteaux-France, September 19 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs and part of Recordati Group, today announce...

RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY Milan, 15 April 2019 – Recordati S.p.A. will be hosting a meeting with the financial community on: Thursday 9 May at 10:30 am GMT (Registration at 9:30 am GMT) London Stock Exchange 10 Paternoster Square, London Recordati’s first quarter 2019 results and the Group’s development strategy and objectives for the period 2019-2021 will be presented at this meeting. The meeting will be held in English. Anyone wishing to attend must register by...

RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIVIDEND € 0.92 (+8.2%). Consolidated revenues € 1,352.2 million, +5.0%. EBITDA (1) € 499.1 million, +9.8% Operating income € 442.2 million, +8.8%. Net income € 312.4 million, +8.2%. Net financial position (2) : net debt of € 588.4 million. Dividend for 2018 € 0.92 per share, of...

RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%. Consolidated revenues € 1,352.2 million, +5.0%. EBITDA (1) € 499.1 million, +9.8% Operating income € 442.2 million, +8.8%. Net income € 312.4 million, +8.2%. Net financial position (2) : net debt of € 588.4 million. Acquisition of the European and other market rights to Cystagon® from Mylan. Acquisition of Natural Point S.r.l. in...

RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN Milan, 6 February 2019 – Recordati announces the signing of a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc., for the exclusive rights to commercialize Juxtapid®, currently approved for the treatment of homozygous familial hypercholesterolemia (HoFH), in Japan. The agreement includes a right of first negotiation for product commercialization in Japan of any potential new indications...

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA ® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a Recordati group company dedicated to providing treatment for patients with unmet medical needs suffering from rare diseases, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, granting Orphan Europe exclusive rights to Ledaga® worldwide,...

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA ® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a Recordati group company dedicated to providing treatment for patients with unmet medical needs suffering from rare diseases, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, granting Orphan Europe exclusive rights to Ledaga® worldwide,...

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA ® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a Recordati group company dedicated to providing treatment for patients with unmet medical needs suffering from rare diseases, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, granting Orphan Europe exclusive rights to Ledaga® worldwide,...

RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR MSUD Milan, 5 November 2018 – Recordati today announced that the European Commission (EC) has granted Orphan Drug Designation to Orphan Europe’s (a Recordati group company) investigational product REC 0545 for the treatment of maple syrup urine disease (MSUD). This is the first time that an Orphan Drug Designation has been granted in this indication. MSUD is a rare genetic metabolic disorder in which the body is...

The 2019 € 100.000 Award will be dedicated to the promotion and recognition of excellence in orphan disease treatment research . Milan, September 2018 The International Prize for Scientific Research Arrigo Recordati has announced the Call for Nominations for the Ninth Edition of the Award. The International Prize for Scientific Research was established in 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati to carry on his legacy and to inspire researchers to make...

RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST HALF 2018. REVENUES +6.9%, OPERATING INCOME +14.1%, NET INCOME +11.7%. Consolidated revenues € 696.1 million, +6.9%. EBITDA (1) € 260.0 million, +16.1% Operating income € 231.9 million, +14.1%. Net income € 164.2 million, +11.7%. Net financial position (2) : net debt of € 556.4 million. Shareholders’ equity € 927.2 million. Milan, 26 July 2018 – The Board of Directors of Recordati S.p.A. approved the Group’s consolidated...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......